ProCE Banner Activity

Key NAFLD/NASH Studies Influencing My Practice Following AASLD 2019

Conference Coverage
Audio

Listen to downloadable audio from a live Webinar reviewing the most clinically relevant new NAFLD/NASH data. Topics include global disease burden, treatments in development, and disease monitoring.

Released: November 22, 2019

Expiration: November 20, 2020

No longer available for credit.

Share

Faculty

Zobair M. Younossi

Zobair M. Younossi, MD, MPH, FACP, FACG

Executive Director, Center for Liver Diseases
Inova Fairfax Hospital
Executive Director of Research
Inova Health System
Professor of Medicine
Virginia Commonwealth University, Inova Campus
Annandale, Virginia

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Gilead Sciences, Inc.

Intercept Pharmaceuticals

Faculty Disclosure

Primary Author

Zobair M. Younossi, MD, MPH, FACP, FACG

Executive Director, Center for Liver Diseases
Inova Fairfax Hospital
Executive Director of Research
Inova Health System
Professor of Medicine
Virginia Commonwealth University, Inova Campus
Annandale, Virginia

Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD, has disclosed that he has received consulting fees or funds for research support from Allergan, Bristol-Myers Squibb, Echosens, Gilead Sciences, HistoIndex, Intercept, Merck, Novartis, Novo Nordisk, Quest Diagnostics, Siemens, Shinogi, Terns, and Viking.